Literature DB >> 28383016

Erratum: SC83288 is a clinical development candidate for the treatment of severe malaria.

Stefano Pegoraro, Maëlle Duffey, Thomas D Otto, Yulin Wang, Roman Rösemann, Roland Baumgartner, Stefanie K Fehler, Leonardo Lucantoni, Vicky M Avery, Alicia Moreno-Sabater, Dominique Mazier, Henri J Vial, Stefan Strobl, Cecilia P Sanchez, Michael Lanzer.   

Abstract

Entities:  

Year:  2017        PMID： 28383016      PMCID： PMC5384206          DOI： 10.1038/ncomms15273

Source DB:  PubMed          Journal:  Nat Commun        ISSN： 2041-1723            Impact factor:   14.919


× No keyword cloud information.
This Article contains errors in Figs. 1 and 8 that were introduced during the production process. The compound on the lower right side of Fig. 1 is labelled incorrectly and should be labelled ‘SC83288'. The correct version of Fig. 1 appears below as Fig. 1. In Fig. 8c, ‘SC83458 selected' should read ‘SC81458 selected' and in Fig. 8d ‘SC81758' should read ‘SC81458'. The correct version of Fig. 8 appears below as Fig. 2.
Figure 1
Figure 2
  1 in total

1.  SC83288 is a clinical development candidate for the treatment of severe malaria.

Authors:  Stefano Pegoraro; Maëlle Duffey; Thomas D Otto; Yulin Wang; Roman Rösemann; Roland Baumgartner; Stefanie K Fehler; Leonardo Lucantoni; Vicky M Avery; Alicia Moreno-Sabater; Dominique Mazier; Henri J Vial; Stefan Strobl; Cecilia P Sanchez; Michael Lanzer
Journal:  Nat Commun       Date:  2017-01-31       Impact factor: 14.919
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.